SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: “Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?” by Manzo et al. Joint Bone Spine 2021;88:105150-Reference-Cited by-同舟云学术

SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: “Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?” by Manzo et al. Joint Bone Spine 2021;88:105150

Published:2022-01 Issue:1 Volume:89 Page:105282
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Cadiou Simon,Perdriger Aleth,Ardois Samuel,Albert Jean-David,Berthoud Olivia,Lescoat Alain,Guggenbuhl Pascal,Robin François

Publisher

Elsevier BV

Subject

Rheumatology

Reference8 articles.

1. Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?;Manzo;Joint Bone Spine,2021

2. SARS-CoV-2 infection triggering a giant cell arteritis;Riera-Martí;Med Clin (Engl Ed),2021

3. IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression;Tharmarajah;J Infect,2021

4. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial;Spiera;Semin Arthritis Rheum,2021

5. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City;Barbhaiya;Ann Rheum Dis,2021

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Takayasu – Arteriitis nach COVID-19-Infektion bei einer 26 Jahre alten Patientin mit Morbus Crohn;Zeitschrift für Gastroenterologie;2024-02-28

2. COVID-19 vaccine-associated vasculitis: A systematic review;SAGE Open Medicine;2024-01

3. Case report of transient polymyalgia rheumatica after receiving the first dose of the BNT162b2 mRNA COVID-19 vaccine;SAGE Open Medical Case Reports;2024-01

4. Giant Cell Arteritis after COVID-19 Vaccination with Long-Term Follow-Up: A Case Report and Review of the Literature;Medicina;2023-12-06

5. Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran);Therapies;2023-09